Table 2. Association of RRAS expression with clinicopathological features of NPC.
| Variable | No. | RRAS expression | P value (χ2-test) | |
|---|---|---|---|---|
| Low (n=32) | High (n=33) | |||
| Gender | 0.341 | |||
| Female | 15 | 9 (60.0) | 6 (40.0) | |
| Male | 50 | 23 (46.0) | 27 (54.0) | |
| Age | 0.108 | |||
| <45 | 30 | 18 (60.0) | 12 (40.0) | |
| ≥45 | 35 | 14 (40.0) | 21 (60.0) | |
| EA/IgA | 0.388 | |||
| <1:20 | 31 | 17 (54.8) | 14 (45.2) | |
| ≥1:20 | 34 | 15 (44.1) | 19 (55.9) | |
| VCA/IgA | 0.953 | |||
| <1:160 | 12 | 6 (50.0) | 6 (50.0) | |
| ≥1:160 | 53 | 26 (49.1) | 27 (50.9) | |
| Clinical staging | 0.019* | |||
| I–III | 34 | 12 (35.3) | 22 (64.7) | |
| VI | 31 | 20 (64.5) | 11 (35.5) | |
| Distant metastasis | 0.082 | |||
| No | 47 | 20 (42.6) | 27 (57.4) | |
| Yes | 18 | 12 (66.7) | 6 (33.3) | |
*P<0.05. NPC, nasopharyngeal carcinoma.